Seer Inc
SEER
$1.75
Closing
▲3.55%
1D
▼-9.79%
YTD
Market cap
$113.35M
52 week high
$5.61
52 week low
$1.46
Volume
172,791
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$113.35M
Analysts' Rating
HOLD
Price Target (Mean)
10
Total Analysts
3
P/E
Operating Margin
-620.98%
Beta
1.61
Revenue Growth (Annual)
134.14%
52 week high
$5.61
52 week low
$1.46
Div. Yield
%
EPS Annual Growth
-10.85
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a gateway to the proteome. The Company’s initial product, the Proteograph Product Suite (Proteograph), is an integrated solution that includes engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. Proteograph leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. Its engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide level, including protein variants. It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product suite and is selling and marketing the Proteograph for research use only (RUO).
